Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.
性状
Liquid
IC50 & Target[1][2]
IC50: 0.6 nM (PD-1)
体外研究(In Vitro)
Pembrolizumab (MK-3475) increases the secretion of cytokines IFN-γ, TNF-α and the apoptotic cell death of A549 cells. Pembrolizumab improves the αROR1-CAR T-mediated cytotoxicity, and reduces tumorigenesis in the co-cultured αROR1-CAR T and A549 cells by blocking PD-1::PD-L1 interaction in αROR1-CAR T cells. has not independently confirmed the accuracy of these methods. They are for reference only.Cell Cytotoxicity Assay
体内研究(In Vivo)
Pembrolizumab inhibits tumor size in A549 xenograft mice pretreated by pressure. has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: Six-week-old male BALB/c athymic nude mice
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
ClinicalTrial
参考文献
[1]. Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017 Aug 16. pii: S0140-6736(17)31601-X.[2]. Zhenglin Ou, et al. Pressure increases PD?L1 expression in A549 lung adenocarcinoma cells and causes resistance to anti?ROR1 CAR T cell?mediated cytotoxicity, Sci Rep